Market research proposal for a cell-free protein manufacturing system

最近的生物医学进步正在彻底改变我们处理患者健康的方式。然而，与许多基于蛋白质的实验室试剂相关的高昂成本限制了生物医学的进展速度。再生医学研究尤其如此，由于这些试剂的市场价格极高，获取细胞因子、抗体和生长因子的途径受到阻碍。我们已经创建了一个自动化的无细胞蛋白质制造平台，可以在几个小时内快速生产和纯化任何规模的蛋白质，包括细胞因子、抗体和生长因子。这与目前基于细胞的技术形成了鲜明对比，这些技术可能需要数周时间才能表达和纯化所需的蛋白质，而且无论规模大小，都需要大量的前期投资。我们的自动化无单元制造平台允许准时生产和灵活扩展，这显著降低了我们的资本和库存成本。这反过来又意味着，最终用户可以以当前市场价格的一小部分获得大量实验室试剂，如细胞因子、抗体和生长因子。这也意味着他们可以很容易地用融合标签修改他们想要的蛋白质(例如，用于纯化或荧光)，以适应他们特定的实验和协议。这是一份I2I市场评估拨款的申请。此评估的目标是接触行业和潜在客户，以确定客户需求和目标市场。这将有助于了解和阐明我们的价值主张，这将使我们能够优化我们的市场进入战略，使我们的技术成功商业化。

Recent biomedical advancements are revolutionizing the way we approach patient health. However, the exorbitant costs associated with many protein-based laboratory reagents limit the rate of progress in biomedicine. This is particularly true for regenerative medicine research, where access to cytokines, antibodies and growth factors is hampered by the extremely high market price of these reagents. We have created an automated cell-free protein manufacturing platform that can rapidly produce and purify proteins, including cytokines, antibodies and growth factors, at any scale and within a few hours. This is in contrast with current cell-based technologies that could take weeks to express and purify a desired protein, and that require large upfront investments regardless of scale. Our automated cell-free manufacturing platform allows just-in-time production and agile scaling, which significantly minimizes our capital and inventory costs. This, in turn, means that end users can have access to a large library of laboratory reagents such as cytokines, antibodies and growth factors at a fraction of their current market price. It also means that they can readily modify their desired proteins with fusion tags (e.g. for purification or fluorescence) that suit their specific experiments and protocols.This is an application for an I2I Market Assessment grant. The goal of this Assessment is to reach out to the industry and potential customers to identify customer needs and target markets. This will help inform and articulate our value proposition, which will allow us to optimize our market entry strategy for successful commercialization of our technology.